![logo](/logos/ENTA.webp)
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
11.54 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Enanta Pharmaceuticals, Inc. |
Symbool | ENTA |
Munteenheid | USD |
Prijs | 11.54 |
Beurswaarde | 244,516,444 |
Dividendpercentage | 0% |
52-weken bereik | 8.08 - 17.8 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jay R. Luly Ph.D. |
Website | https://www.enanta.com |
An error occurred while fetching data.
Over Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)